Stem Cell Therapy
Stem Cell Therapy for Rheumatoid Arthritis and Lupus
Stem Cell Malaysia· 7 min read
Living with an autoimmune disease means living with uncertainty. Rheumatoid arthritis (RA) can cause morning stiffness that lasts for hours, swollen hands and progressive joint damage, while systemic lupus erythematosus (SLE) can affect the skin, joints, kidneys, blood and brain, with flares that come and go unpredictably.
In Malaysia, lupus is recognised as a significant condition, and hospital rheumatology clinics report that it is more frequently seen among women of Chinese and Indian descent than among some other groups. Advances in medication have transformed outcomes, yet many patients still face side effects, incomplete disease control or fear of long-term steroid use. That is why stem cell therapy attracts interest.
This article looks at what research shows, what remains unproven and how to approach these treatments responsibly.
Understanding the Diseases
Rheumatoid arthritis is a chronic autoimmune condition in which the immune system attacks the joint lining, leading to pain, swelling and eventual erosion of bone and cartilage. It can also affect the lungs, eyes and blood vessels.
Lupus is a multi-system autoimmune disease in which the body produces antibodies against its own tissues. Kidney involvement (lupus nephritis) is a major concern and can lead to kidney failure if not controlled.
Both conditions are managed rather than cured. Standard treatment, guided by rheumatologists, includes:
| Condition | Common treatments |
|---|---|
| Rheumatoid arthritis | Methotrexate and other conventional DMARDs, biologics such as TNF inhibitors, JAK inhibitors, short-term steroids, physiotherapy |
| Lupus | Hydroxychloroquine, corticosteroids, azathioprine, mycophenolate, cyclophosphamide, belimumab and other targeted agents, sun protection and blood pressure control |
Early and consistent treatment prevents damage far better than any experimental option can repair it later.
Why Stem Cells Are Being Studied
Two very different stem cell approaches are used in autoimmune disease research, and it is important not to confuse them.
1. Haematopoietic stem cell transplantation (HSCT)
In severe, treatment-resistant autoimmune disease, some centres use high-dose chemotherapy to reset the immune system, followed by infusion of the patient's own blood-forming stem cells. This is a demanding hospital procedure with real risks, including serious infection, and is reserved for carefully selected patients in specialist centres. Registry data and small trials suggest that a proportion of patients with refractory lupus achieve prolonged remission, though treatment-related mortality has been reported and has declined with experience. HSCT is not commonly used for RA.
2. Mesenchymal stem cell (MSC) therapy
MSCs, most often from umbilical cord or fat tissue, are studied for their ability to calm immune responses, influence T-cells and B-cells, and release anti-inflammatory factors. This is the approach commonly advertised by private clinics, and it is very different from HSCT. It involves no chemotherapy conditioning, but the evidence base is smaller and less certain.
What the Research Shows
Rheumatoid arthritis
Early phase trials of umbilical cord and adipose-derived MSCs have reported that infusions were generally well tolerated, with some patients showing improvements in disease activity scores and inflammatory markers. Many studies were small, open-label and used MSCs alongside existing medications, which makes it difficult to attribute benefit to the cells alone. Results have often been short-lived in some participants, and no MSC product is established as standard RA treatment.
Lupus
Several Chinese studies of allogeneic umbilical cord MSCs in active lupus, especially lupus nephritis, reported improvements in disease activity scores, proteinuria and serological markers in a proportion of patients, with acceptable short-term safety. Later, larger controlled studies and meta-analyses have been more cautious, noting that many trials are small, vary in design and lack long-term follow-up.
Key Limitations of the Evidence
- Small trials. Most studies enrol dozens, not hundreds, of participants.
- Different products. Cell source, dose and schedule vary widely.
- Background therapy. Patients often keep taking immunosuppressive drugs, so improvement may reflect combined effects.
- Short follow-up. Autoimmune disease follows a relapsing course, so long-term outcomes matter.
- Publication bias. Positive small studies are more likely to be reported.
For an overview of how donor and self-derived cells differ, see autologous or allogeneic stem cells for regenerative treatment. Most lupus MSC research uses donor umbilical cord cells rather than the patient's own cells, partly because cells from a person with active autoimmune disease may not function optimally.
Risks to Consider
Autoimmune patients often take drugs that suppress the immune system, which raises infection risk. Additional concerns include:
- Infusion reactions, fever or allergic responses
- Infection from contaminated or poorly processed products
- Blood clots in susceptible patients
- Possible disease flares if medication is reduced prematurely
- Serious complications from HSCT
You can read more in our guide on stem cell therapy side effects reported in clinical studies.
The most dangerous decision is stopping prescribed medication because a clinic suggests stem cells will "replace" it. Uncontrolled lupus can cause irreversible kidney or organ damage, and uncontrolled RA can lead to permanent joint deformity.
The Malaysian Context
Malaysia has public and private rheumatology services in major centres such as the Klang Valley, Penang, Johor Bahru and Kuching, and specialist societies provide guidance for RA and lupus care. Some private clinics advertise stem cell programmes for autoimmune disease, often priced in the range of tens of thousands of ringgit.
Before considering these offers:
- Speak to your rheumatologist first. A reputable clinic should welcome collaboration with your existing doctor.
- Ask whether treatment is part of a registered clinical trial or a private service.
- Verify the regulatory status of the product. Our guide to Malaysian NPRA rules on cell and gene therapy products explains how registration works.
- Check the cost structure and whether repeated infusions are planned. Read how many stem cell sessions are usually needed to understand common package designs.
Comparing Options
| Option | Evidence level | Approximate cost context in Malaysia | Main consideration |
|---|---|---|---|
| Conventional DMARDs and immunosuppressants | Strong | Low to moderate; heavily subsidised in public hospitals | First-line, well studied |
| Biologic and targeted therapy | Strong | Moderate to high; some access via public programmes or insurance | Screening for infection needed |
| MSC infusion | Emerging | Often RM 15,000 to RM 60,000+ privately | Experimental in most contexts |
| Autologous HSCT | Moderate for severe refractory lupus and some other diseases | Hospital-based, specialist centre | High-risk procedure |
Lifestyle and Supportive Care That Still Matter
- Stop smoking: It worsens RA risk and severity.
- Protect against sun exposure if you have lupus.
- Keep vaccinations up to date, guided by your specialist.
- Stay active: Gentle exercise protects joints and mood.
- Monitor kidney and blood tests regularly.
- Plan pregnancy carefully: Lupus and RA medications need review before conception.
- Seek mental health support: Fatigue and pain increase the risk of depression.
Red Flags in Autoimmune Stem Cell Marketing
- Claims of "curing" lupus or RA
- Advice to reduce or stop medication
- Testimonials instead of published data
- Products described as "natural" or "safe for everyone"
- No information on cell source, dose or laboratory
- Promises of immediate results
Questions to Ask Your Doctor
- Is my disease controlled, or would treatment adjustment be more effective first?
- Is there a clinical trial I could join through a hospital or university?
- What are the specific risks given my medications?
- How will disease activity be measured before and after treatment?
- What happens if I flare?
Frequently Asked Questions
Can stem cells cure lupus or rheumatoid arthritis?
No cure has been established. Some studies show reduced disease activity in selected patients.
Can I stop my medication after stem cell therapy?
Never stop medication without your specialist's advice. Trials typically continued standard drugs.
Is stem cell therapy better than biologic drugs?
Biologics have far stronger evidence and regulatory approval for their indications.
Is HSCT the same as clinic stem cell injections?
No. HSCT involves chemotherapy and hospital care and is completely different from an MSC infusion.
Conclusion
Stem cell therapy for RA and lupus is a scientifically interesting but still evolving field. HSCT may offer options for a small group with severe, refractory disease in expert centres, while MSC infusions remain largely experimental. The best decisions are made alongside your rheumatologist, with clear evidence, honest cost discussions and continued adherence to proven therapy.
This article is for education only and does not replace medical advice. Never change autoimmune medication without consulting your specialist.
